PanGenetics announces acquisition of PG110 anti-NGF antibody to treat chronic pain by Abbott
13-Nov-2009 -
PanGenetics, developing PG110, a humanized antibody to Nerve Growth Factor (NGF), announced it has entered into an agreement with Abbott under which Abbott will acquire the global rights to this novel biologic. PG110 is currently in a Phase 1 clinical trial in patients with osteoarthritis and ...
chronic pain
clinical trials
growth factors
+5